NCT06257017View on ClinicalTrials.gov

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
Muscle Invasive Bladder Urothelial CarcinomaMuscle-Invasive Bladder Carcinoma
Interventions
DRUG

gemcitabine

1,000 mg/m2 intravenous gemcitabine on day 1 and day 8

DRUG

Cisplatin

70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

All Listed Sponsors
collaborator

Pamela Youde Nethersole Eastern Hospital

OTHER

collaborator

Queen Mary Hospital, Hong Kong

OTHER

lead

Yung NA

OTHER